Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction

Zannad, Faı̈ez; Gille, Bertrand; Grentzinger, A.; Bruntz, Jean-François; Hammadi, Mokrane; Boivin, Jean‐Marc; Hanotin, Corinne; Igau, Bruno; Drouin, P

doi:10.1067/mhj.2002.124403

Cited by 67 publications

(48 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In obese patients, sibutramine (10-20 mg/day for 3-6 months) reduced left ventricular mass whereas no significant change was observed in the placebo group. [75,76] This reduction correlated with the decrease in body weight. [76] Thus, combined to hypocaloric diet, sibutramine-associated weight reduction in obese individuals has positive effect on reduction of BP and contributes to reduce left ventricular mass, the hallmark of markers of preclinical CVD and most powerful predictor of adverse outcome.…”

Section: Left Ventricular Hypertrophymentioning

confidence: 91%

Cardiovascular Risk-Benefit Profile of Sibutramine

Scheen

2010

American Journal Cardiovascular Drugs

View full text Add to dashboard Cite

SUMMARYSibutramine is a combined norepinephrine and serotonin reuptake inhibitor used as an antiobesity agent to reduce appetite and promote weight loss in combination with diet and exercise. At a daily dose of 10-20 mg, it was initially considered to have a good safety profile as it does not induce primary pulmonary hypertension or adverse effects on cardiac valves, in contrast to what was previously reported with some other anti-obesity agents. However, it exerts

show abstract

Section: Left Ventricular Hypertrophymentioning

confidence: 91%

Cardiovascular Risk-Benefit Profile of Sibutramine

Scheen

2010

American Journal Cardiovascular Drugs

View full text Add to dashboard Cite

show abstract

“…[5][6][7][8] Weight loss can also result in a significant fall in systemic blood pressure and heart rate even when dietary sodium intake is not decreased. 8,9 For each kilogram of weight loss, blood pressure is reduced by 2.5 mmHg (systolic) and 1.7 mmHg (diastolic), 10 frequently allowing a dose reduction or even withdrawal of antihypertensive drugs.…”

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of sibutramine in 2225 subjects with cardiovascular risk factors: short-term, open-label, observational study

Gaciong

Placha

2005

J Hum Hypertens

View full text Add to dashboard Cite

This study aims to determine the efficacy and tolerability of sibutramine hydrochloride in overweight and obese patients with cardiovascular risk factors. This was a 12-week, open-label, observational trial carried out in primary care settings. Patients' data were obtained from questionnaires received from 153 physicians. A total of 2225 overweight and obese (BMIX27 kg/m 2 ) patients received sibutramine in single daily doses of 10 and/or 15 mg. The study population included patients in general good health and with controlled hypertension (41.2%), type II diabetes mellitus (15.6%), hyperlipidaemia (45.5%), and who were chronic tobacco users (smokers) (37.0%). The main outcome measures were changes in body weight, blood pressure and heart rate, and evaluation of reported adverse events. Reduction of body weight of at least 45% from baseline to week 12 was achieved in 2030 (91%) patients and 410% was achieved in 987 (44%) patients. Baseline differences in the percentages of male and female patients, presence or absence of hyperlipidaemia or smoking status did not appear to affect the rate of weight change. Weight loss was less in patients with type II diabetes mellitus and/or controlled systolic hypertension at baseline compared to those patients without these conditions. Mean systolic and diastolic blood pressure and heart rate decreased from baseline to week 12. Overall, sibutramine was well tolerated. In conclusions, treatment with sibutramine resulted in clinically significant weight loss during short-term therapy in obese adults with a range of cardiovascular risk factors.

show abstract

“…43 Indeed, diet has been documented to be at least as effective as aggressive antihypertensive medication in normalization of the elevated left ventricular mass. 43 Moreover, Zannad and co-workers demonstrated that sibutramineassisted weight-loss has beneficial effects on the prevalence of left ventricular hypertrophy in obese individuals 46 ( Figure 5). Finally, weight reduction may reduce heart rate variability and serve as an indicator of less arrhythmogenic events after the successful completion of a diet program.…”

Section: Cardiac Mortality and Obesitymentioning

confidence: 99%

Obesity and target organ damage: the heart

Schunkert

2002

Int J Obes

View full text Add to dashboard Cite

In most patients, coronary atherosclerosis or congestive heart failure develop as an integrated response to multiple cardiovascular risk factors. Obesity increases the prevalence of most cardiovascular risk factors and is the predominant cause of diabetes mellitus and arterial hypertension. Moreover, obesity shifts the manifestation of these risk factors to younger age groups, such that subsequent damage results prematurely in clinically overt cardiac diseases. In addition, due to clustering of obesity-related risk factors, obesity may amplify the risk by synergistic mechanisms acting in parallel. Finally, an elevated body mass index (BMI) results in an increase in heart rate and blood volume, as well as increased systolic and diastolic blood pressure. These changes affect cardiac geometry and mass in addition to the alterations of the coronary vasculature. At the population level, the role of obesity in promoting multiple risk factors and, subsequently, the development of heart diseases cannot be underestimated. In individual patients, however, the clinical presentation may be dominated by obesity-related hypertension, diabetes, metabolic and inflammatory derangements or clinical symptoms of heart failure or coronary artery disease. Weight reduction remains a crucial component of the therapeutic strategy to ameliorate insulin resistance, hypertension and left ventricular hypertrophy, among other risk factors, with profound implications for the individual's prognosis.

show abstract

Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction

Cited by 67 publications

References 31 publications

Cardiovascular Risk-Benefit Profile of Sibutramine

Cardiovascular Risk-Benefit Profile of Sibutramine

Efficacy and safety of sibutramine in 2225 subjects with cardiovascular risk factors: short-term, open-label, observational study

Obesity and target organ damage: the heart

Contact Info

Product

Resources

About